KDC-MN-132 – Kodiac biolabs

Plain-language summaryIntrigue 80 / 100

Liraglutide, sold as Victoza and Saxenda, was the first daily GLP-1 receptor agonist approved for both diabetes (Victoza) and weight loss (Saxenda). It paved the way for the entire GLP-1 obesity drug class. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

The founding daily GLP-1 agonist, now eclipsed by semaglutide on nearly every metric that matters

Look, liraglutide earns its place in the library as the compound that first proved GLP-1 receptor agonism could sustain meaningful weight loss in a real clinical setting. The SCALE obesity program, the LEADER cardiovascular outcomes trial, FDA approvals for both T2DM and chronic weight management: the evidence base is legitimate and well-replicated. The problem is that “legitimate and well-replicated” now describes a 2010-era compound that’s been clearly outclassed in nearly every direction that matters to a bench investigator today.

The mechanism is GLP-1R agonism, single-target, well-understood. The palmitoyl fatty acid chain and albumin-binding strategy for extending half-life to roughly 13 hours was genuinely clever engineering at the time, enabling once-daily subcutaneous dosing when that was the frontier. But the same albumin-binding logic, applied to a longer chain and a refined backbone, gave Novo Nordisk semaglutide: weekly dosing, roughly double the weight-loss efficacy, a cardiovascular mortality signal, a renal protection signal, and eventually oral bioavailability. The engineering that made liraglutide work also showed researchers exactly how to do it better.

On differentiation, this is where liraglutide really struggles. It’s not competitive with semaglutide on efficacy. It’s not competitive with tirzepatide on mechanism breadth. Within the daily-dosing GLP-1 space it has no surviving advantage: dulaglutide is weekly, exenatide extended-release is weekly, semaglutide oral is approved. Daily dosing is a liability, not a feature. Cross-program comparisons between the SCALE and STEP trial families have formalized the hierarchy, with semaglutide delivering roughly 15-17% body weight reduction versus liraglutide’s ~8% in the SCALE trials.

What liraglutide retains is real research utility as a reference compound. If youre running a GLP-1R biology study, liraglutide is a well-characterized probe with known receptor-binding affinity constants, decades of pharmacokinetic data, and a predictable safety profile at research doses. It serves as a positive control in screens, and the LEADER cardiovascular data provides a concrete clinical comparator for any new compound trying to demonstrate CV benefit in the GLP-1 class. Thats genuine bench value, but it’s the bench value of an established reference tool, not an active investigation target.

We think liraglutide belongs in the library primarily as context: what the first generation of long-acting GLP-1R agonists looked like, and why the class evolved the way it did. For a researcher trying to understand GLP-1 biology deeply, it’s worth knowing. For a researcher trying to identify the next compelling metabolic target, it mostly points toward semaglutide, tirzepatide, or the triple agonists further along the development curve. Honest assessment: this is a workhorse that has already done its most important work.

Novelty: 22
Mechanism promise: 45
In-category differentiation: 15
Evidence quality: 78
Translational signal: 70
Research bench value: 55

Rationale Liraglutide defined the GLP-1 obesity category and carries genuinely strong evidence (SCALE program, LEADER CV outcomes trial), but single-target GLP-1R agonism at daily dosing is now a legacy profile; semaglutide’s superior efficacy and weekly schedule have made liraglutide a historical reference rather than a live research priority, and differentiation scores accordingly low.

Daily GLP-1 receptor agonist

A daily-dosing GLP-1 analog FDA-approved as Victoza (T2DM, 2010) and Saxenda (obesity, 2014); the predecessor of semaglutide.

Abstract

Liraglutide (Victoza, Saxenda; CAS 204656-20-2; molecular weight 3751.20) is a long-acting GLP-1 receptor agonist developed by Novo Nordisk and approved by the FDA for T2DM (2010) and obesity (2014). The compound features a 16-carbon fatty acid (palmitoyl) chain attached to lysine 26 via a glutamic acid spacer, enabling reversible albumin binding for extended half-life of approximately 13 hours, supporting once-daily subcutaneous dosing. Liraglutide was the first GLP-1 agonist approved for chronic weight management. Approved doses are 0.6 to 1.8 mg daily for T2DM and titrated to 3 mg daily for obesity.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-132Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-132

Liraglutide

Abstract

Read the full monograph